Example C A Case Study for the Fused Strategy

HDACs represent a rational monotherapy or combination therapy for cancer treatment. Several HDAC inhibitors (HDACi s) are currently under clinical trials either as monotherapy or combination therapy agents against cancer [43]. The hydroxamate-containing HDACi s trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA, 13) exhibit the highest potency with excellent efficacy. 

In another aspect, statins have recently been shown to be effective for cancer prevention in observational, preclinical, and certain randomized controlled studies [44]. Statins, such as lovastatin (14) and atorvastatin, are known to reduce serum cholesterol levels through competitive inhibition at 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR). The HMGR inhibitors (HMGRi s) are effectively used to decrease the incidence of cardiovascular and cerebrovascular disorders and to prevent cardiovascular disease (CVD). Statins possess an established record of safety and efficacy in human CVD prevention. 

---